Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0Q7ZQ
|
||||
| Former ID |
DAP001132
|
||||
| Drug Name |
Succinylcholine
|
||||
| Synonyms |
Anectine; Diacetylcholine; Ditilin; Ditiline; Listenon; Lysthenon; Quelicin; SCK; Succicuran; Succinocholine; Succinoylcholine; Succinylbischoline; Succinyldicholine; Sucostrin; Suxamethonium; Dicholine succinate; Succinyl choline; Anectine (TN); Scoline (TN); Succinic acid, diester with choline; Succinic acid, diester with choline chloride; Choline, succinate (ester); Choline, succinate (2:1) (ester); Trimethyl-[2-[4-oxo-4-(2-trimethylazaniumylethoxy)butanoyl]oxyethyl]azanium diio; Trimethyl-[2-[4-oxo-4-[2-(trimethylazaniumyl)ethoxy]butanoyl]oxyethyl]azanium; 2,2'-[(1,4-DIOXOBUTANE-1,4-DIYL)BIS(OXY)]BIS(N,N,N-TRIMETHYLETHANAMINIUM)
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Spasms; Pain [ICD9: 338,780; ICD10:R52, G89] | Approved | [1], [2], [3] | ||
| Therapeutic Class |
Analgesics
|
||||
| Company |
Sandoz Canada Inc
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C14H30N2O4+2
|
||||
| InChI |
InChI=1S/C14H30N2O4/c1-15(2,3)9-11-19-13(17)7-8-14(18)20-12-10-16(4,5)6/h7-12H2,1-6H3/q+2
|
||||
| InChIKey |
AXOIZCJOOAYSMI-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 306-40-1
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
9749, 7658696, 7672825, 7980692, 8153258, 11111825, 12075317, 14710537, 14873361, 15047415, 26744180, 29224368, 46506023, 47515447, 49903255, 50111236, 53812664, 53812668, 57322704, 57820299, 77403683, 81065590, 85209629, 90341285, 92309310, 103194169, 103957129, 104308882, 114917406, 118518886, 124750220, 124752895, 124881499, 124881500, 126408127, 127473514, 134338377, 134974288, 137004055, 141317082, 144035335, 152198910, 160963550, 175265529, 175442114, 176484556, 178100830, 179116901, 215683529, 226426545
|
||||
| ChEBI ID |
ChEBI:45652
|
||||
| SuperDrug ATC ID |
M03AB01
|
||||
| SuperDrug CAS ID |
cas=000306401
|
||||
| Target and Pathway | |||||
| Target(s) | Muscarinic acetylcholine receptor M3 | Target Info | Antagonist | [4], [5] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Cholinergic synapse | |||||
| Regulation of actin cytoskeleton | |||||
| Insulin secretion | |||||
| Salivary secretion | |||||
| Gastric acid secretion | |||||
| Pancreatic secretion | |||||
| PANTHER Pathway | Alzheimer disease-amyloid secretase pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Muscarinic acetylcholine receptor 1 and 3 signaling pathway | |||||
| PathWhiz Pathway | Gastric Acid Production | ||||
| Reactome | Muscarinic acetylcholine receptors | ||||
| Acetylcholine regulates insulin secretion | |||||
| G alpha (q) signalling events | |||||
| WikiPathways | Monoamine GPCRs | ||||
| Calcium Regulation in the Cardiac Cell | |||||
| Regulation of Actin Cytoskeleton | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| Integration of energy metabolism | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| GPCRs, Other | |||||
| References | |||||
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 008453. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4004). | ||||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
| REF 4 | The involvement of histaminic and muscarinic receptors in the bronchoconstriction induced by myorelaxant administration in sensitized rabbits. Anesth Analg. 2008 Dec;107(6):1899-906. | ||||
| REF 5 | Neuromuscular relaxants as antagonists for M2 and M3 muscarinic receptors. Anesthesiology. 1998 Mar;88(3):744-50. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.